Drug Type Synthetic peptide |
Synonyms BIM-23A760, TBR 760, TBR-760 |
Mechanism D2 receptor agonists(Dopamine D2 receptor agonists), SSTR2 agonists(Somatostatin receptor 2 agonists), SSTR5 agonists(Somatostatin receptor 5 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC86H116N16O12S4 |
InChIKeyWLBJBODHTIKYSL-JFPOTJHNSA-N |
CAS Registry868562-36-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Functioning Pituitary Neuroendocrine Tumor | Phase 2 | - | Tiburio Therapeutics, Inc.Startup | 01 May 2020 |
Pituitary Neoplasms | Phase 2 | - | Tiburio Therapeutics, Inc.Startup | 01 May 2020 |
Malignant Carcinoid Syndrome | Phase 2 | AT | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | BE | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | CZ | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | FI | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | FR | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | DE | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | IE | 01 Feb 2010 | |
Malignant Carcinoid Syndrome | Phase 2 | IL | 01 Feb 2010 |
Phase 2 | 8 | jbuhyjwdbq(yktghxmqhm) = ozekfbdxuz vzusmjhbzf (sdmvfywjub, tefgzjgjwb - cohskncxjb) View more | - | 07 Sep 2015 |